Media headlines about CTI BioPharma (NASDAQ:CTIC) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CTI BioPharma earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6019588994836 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of CTI BioPharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine lowered shares of CTI BioPharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th.
Shares of CTI BioPharma (CTIC) traded down $0.16 during trading on Wednesday, reaching $2.86. 119,872 shares of the company’s stock traded hands, compared to its average volume of 181,422. The company has a market cap of $123.32, a price-to-earnings ratio of -2.79 and a beta of 0.53. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.19 and a quick ratio of 2.17. CTI BioPharma has a 12-month low of $2.45 and a 12-month high of $5.07.
CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.04. The firm had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.30 million. CTI BioPharma had a negative net margin of 96.91% and a negative return on equity of 209.67%. sell-side analysts forecast that CTI BioPharma will post -1.2 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect CTI BioPharma (CTIC) Stock Price” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/31/cti-biopharma-ctic-receiving-somewhat-positive-news-coverage-study-finds.html.
About CTI BioPharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.